This would enable FRE to initially go to market with Nasodine as...

This would enable FRE to initially go to market with Nasodine as a "Listed Complimentary Medicine" bringing in revenue and allow them to pursue the "Assessed Listed Complimentary Medicine" approvals at a later date.

A reasonable assesment of FREs go-to-market options. However, a Complementary strategy brings the economics of Nasodine into the spotlight.

Complementary medicines are sold in typically competitive markets and are often acutely price sensitive. Does Firebrick have the COGS for Nasodine established? Can FRE generate a reasonable ROI from a product that will undoubtedly retail at a substantial discount to an Rx product?

Sales of Complementary products correlate with above the line marketing spend. Will FRE be able to raise money to spend promoting Nasodine complementary?

Downgrading a Therapeutic candidate to a Complementary product is fraught with danger for retail shareholders. Good examples of “biotech” companies going down the toilet based on this strategy are Anagenics (formerly Cellmid) and Avecho (formerly Phospagenics).